Business Wire

NJ-IEEE

15.11.2021 16:32:07 CET | Business Wire | Press release

Share
City of Vienna Earns IEEE AI Ethics Certification Mark; Reinforcing Commitment to Digital Humanism Strategy

IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE SA) today announced that the City of Vienna has become the first city worldwide to earn the IEEE CertifiAIEd AI Ethics (AIE) Certification Mark to advance the city’s Digital Humanism strategy.

"With artificial intelligence, we can make many tasks in administration more efficient and faster. As the City of Vienna, we are taking on a pioneering role here," says Peter Hanke, City Councillor for Economic Affairs. "Particularly in direct contact with people and especially in dealing with data, caution is required. People are at the center of our considerations."

The IEEE CertifAIEd mark recognizes that a product, service, or system has been verified to meet relevant ethical criteria, contributing towards a greater level of confidence and demonstrating a proactive approach to building public trust in AI systems. There are currently four sets of criteria available for IEEE CertifiAIEd certification:

  • Transparency criteria relate to values embedded in a system design, and the openness and disclosure of choices made for development and operation.
  • Accountability criteria recognize that the system/service autonomy and learning capacities are the results of algorithms and computational processes designed by humans and organizations that remain responsible for their outcomes.
  • Algorithmic bias criteria relate to the prevention of systematic errors and repeatable undesirable behaviors that create unfair outcomes.
  • Privacy criteria are aimed at respecting the private sphere of life and public identity of an individual, group, or community, upholding dignity.

“IEEE has laid the groundwork for AI Ethics based on principles and standards created by hundreds of our volunteers over the past five years, which are already having a global impact,” said Konstantinos Karachalios, Managing Director of IEEE SA. “IEEE CertifAIEd represents our continued evolution of the AI Ethics ecosystem by establishing a program to inspire trust and a means towards responsible implementation of AI systems that demonstrates an organization’s commitment to upholding human values, dignity, and well-being, and to respecting, protecting and preserving fundamental human rights. We are honored to work with the City of Vienna to support their Digital Humanism platform and to provide the mark for responsible innovation required in today’s world to inspire certified trust for their AI Systems.”

IEEE’s CertifAIEd program aims to enhance confidence in public and private enterprises that realize the benefits of AI ethics by earning certification in the absence of or as a complement to broadly accepted and enforced regulations for AI. As proposed legislation in the EU would require conformity certification for any AI based systems to mitigate any unintended risks, the City of Vienna is addressing these risks and demonstrating the benefits of responsible government innovation by earning the IEEE CertifAIEd mark. In doing so, it sets a precedent for other cities and entities to achieve their aims in a responsible and human-centric manner.

"Data security and data protection must be at the forefront when using AI from the very beginning. That's why we relied on international expertise during the development of the software and had our program ethically certified," said Deputy Director General, Peter Weinelt.

Cities, entities, and individuals interested in learning more about the criteria or getting involved in the program can visit the IEEE CertifAIEd website .

To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook , follow us on Twitter , connect with us on LinkedIn , or on the Beyond Standards Blog .

About the IEEE Standards Association

IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards, and industry solutions shaping a better, safer and sustainable world. For more information, visit https://standards.ieee.org .

About IEEE

IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org .

Link:

ClickThru

Social Media:

https://www.facebook.com/ieeesa/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye